No 02 2025

Boehringer Ingelheim's survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.

The US FDA has extended its review of Novo's Biologics License Application for denecimig in haemophilia A, citing ongoing remediation work at a manufacturing facility. No new timeline for a decision has been communicated.

Lundbeck has presented Phase Ib results for its oral drug candidate Lu AF28996 in advanced Parkinson's disease and has randomized the first patient in the Phase II DARE2 trial.

As an NLS Member, you and your colleagues get discounted tickets to selected life science events. This fall, members can save on Health Design in Finland, FHIM in China, and BIO-Europe in Germany.

The Nobel Assembly at Karolinska Institutet has decided to award the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.

Genmab has reported Phase 2 results for its antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% among 109 treated patients.

FluoGuide has entered a collaboration with medical technology company Leica Microsystems to advance precision surgery for brain tumors by combining its lead product, FG001, with Leica's surgical microscope systems.